CRRTF - Crescita Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.7100
0.0000 (0.00%)
At close: 12:28PM EST
Stock chart is not supported by your current browser
Previous Close0.7100
Open0.7150
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7100 - 0.7100
52 Week Range0.3400 - 0.7100
Volume11,000
Avg. Volume10,500
Market Cap14.91M
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-0.3760
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Crescita Signs Exclusive Distribution Agreement with FILLMED

    Crescita Therapeutics Inc. (TSX: CTX) and (OTC US: CRRTF) ("Crescita" or the "Company"), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that it has entered into a distribution agreement (the "Agreement") with Laboratoires FILLMED (formerly Laboratoires Filorga Medical, "FILLMED") for the exclusive distribution of the ART-FILLER® injectables range and New Cellular Treatment Factor® ("NCTF®") in Canada. FILLMED is a French aesthetic medicine company with expertise in developing aesthetic and cosmetic anti-ageing treatment solutions using hyaluronic acid.

  • Does Crescita Therapeutics Inc. (TSE:CTX) Have A Particularly Volatile Share Price?
    Simply Wall St.

    Does Crescita Therapeutics Inc. (TSE:CTX) Have A Particularly Volatile Share Price?

    Anyone researching Crescita Therapeutics Inc. (TSE:CTX) might want to consider the historical volatility of the share...

  • PR Newswire

    CARBO Ceramics Inc. Director Carla Mashinski Named to the WomenInc. List of Most Influential Corporate Directors

    CARBO Ceramics Inc. (OTCQB: CRRT) ("CARBO" or "the Company") today announced that CARBO Director Carla Mashinski has been named to the WomenInc. magazine's 2019 list of Most Influential Corporate Directors in its Winter 2019 edition. WomenInc.'s Most Influential Corporate Directors issue is a comprehensive listing of female directors, executives, influencers and achievers who are currently contributing leadership to corporate boards.

  • PR Newswire

    CARBO Provides Update on NYSE Delisting, Announces Move to OTCQB Market

    CARBO Ceramics Inc. ("CARBO" or "the Company") today announced that, as anticipated, it received notification from the New York Stock Exchange ("NYSE") of the suspension of trading of the Company's common shares effective today, December 20, 2019, at the close of trading as a result of its failure to meet the NYSE's average global market capitalization continued listing criteria. CARBO expects that its common shares will begin trading on the OTCQB Market under the symbol "CRRT" on December 23, 2019.

  • Is Crescita Therapeutics (TSE:CTX) Using Too Much Debt?
    Simply Wall St.

    Is Crescita Therapeutics (TSE:CTX) Using Too Much Debt?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • CNW Group

    Crescita Reports 2019 Third Quarter Results

    Crescita Reports 2019 Third Quarter Results

  • CNW Group

    U.S. Food and Drug Administration Approves Enhanced Formulation of Pliaglis®

    LAVAL, QC , Nov. 5, 2019 /CNW Telbec/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) ("Crescita"), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that the U.S. Food and Drug Administration ("FDA") approved the enhanced formulation of Pliaglis® (the "Enhanced Formulation") following its statutory six-month review process and in line with the target action date under the Prescription Drug User Fee Act ("PDUFA"). While the U.S. patent covering the original formulation of Pliaglis® expired on September 28 . 2019, the U.S. patent covering the Enhanced Formulation with extended protection to 2031, is in the process of being added to the Orange Book.

  • Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals
    PR Newswire

    Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals

    CALGARY and LAVAL, QC, Oct. 28, 2019 /PRNewswire/ - Sundial Growers Inc. (Nasdaq:SNDL) ("Sundial"), a Canadian licensed producer of cannabis and Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita"), a Canadian commercial dermatology company, today announced a development and licensing agreement (the "Agreement") granting Sundial the worldwide rights to Crescita's proprietary transdermal delivery technologies for the development of topicals containing cannabis and hemp. The Agreement will enable the development of unique, high-quality cannabis and hemp topicals for the Canadian and international non-prescription markets.

  • The Crescita Therapeutics (TSE:CTX) Share Price Has Gained 89% And Shareholders Are Hoping For More
    Simply Wall St.

    The Crescita Therapeutics (TSE:CTX) Share Price Has Gained 89% And Shareholders Are Hoping For More

    Crescita Therapeutics Inc. (TSE:CTX) shareholders might be concerned after seeing the share price drop 18% in the last...

  • PR Newswire

    Crescita Reports Profitable 2019 Second Quarter Results

    Record Revenue of $9.4 Million and Adjusted EBITDA of $5.1 Million LAVAL, QC , Aug. 8, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial ...

  • CNW Group

    United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®

    LAVAL, QC , July 16, 2019 /CNW/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (CTX.TO) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that the United States Patent and Trademark Office ("USPTO") has granted U.S. Patent No. 10,350,180 for an enhanced formulation of Pliaglis® which provides extended patent protection until 2031. "The newly granted U.S. patent further strengthens our intellectual property portfolio," said Serge Verreault , President and CEO of Crescita. Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain.

  • PR Newswire

    Crescita Therapeutics to Host Investor Webcast on July 24, 2019

    LAVAL, QC, July 11, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (CTX.TO) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that it will host a webcast investor presentation on Wednesday, July 24, at 11:00 AM ET. During the webcast, Serge Verreault, Crescita's President and CEO, will provide an introduction to the Company through a PowerPoint presentation that will cover the key areas of Crescita's business, including an overview of the Company's commercial and pipeline products, patented transdermal delivery technologies, its strategy, as well as growth opportunities.

  • CNW Group

    Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of €1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy

    LAVAL, QC , July 4, 2019 /CNW/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (CTX.TO) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that it has received the second instalment of € $1.25 million (~CDN $1.88 million ) of the up-front payment related to the out-licensing of Pliaglis in Italy , France , Spain and Portugal , from its partner, Cantabria Labs. The 2nd instalment was received following the completion of the transition activities from Galderma to Cantabria  leading to the first commercial sale of Pliaglis in Italy by the Cantabria sales team. Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain.

  • CNW Group

    Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

    LAVAL, QC , June 26, 2019 /CNW/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) ("Crescita" or the "Company") announced today that the Toronto Stock Exchange (the "TSX") has approved the Company's intention to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares") as appropriate opportunities arise from time to time. Pursuant to the NCIB notice filed with the TSX, the Company intends to acquire up to a maximum of 1,000,000 Common Shares, or approximately 6% of its public float as of June 26, 2019 for cancellation over the next 12 months.

  • CNW Group

    Crescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid

    LAVAL, QC , June 17, 2019 /CNW/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) ("Crescita" or the "Company"), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that it intends to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares") as appropriate opportunities arise from time to time. The Company's normal course issuer bid, which is expected to be for up to 1,000,000 common shares, or approximately 6% of its public float, will be made in accordance with the requirements of the Toronto Stock Exchange (the "TSX") and remains subject to TSX approval.